Cargando…
Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress
SIMPLE SUMMARY: Pancreatic cancer has a dismal 5-year survival rate of 10%, making it one of the deadliest forms of malignancy. The poor prognosis associated with this disease is because it is resistant to almost every type of chemotherapy. Another major hallmark of pancreatic cancer is the presence...
Autores principales: | Mehra, Siddharth, Deshpande, Nilesh, Nagathihalli, Nagaraj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430624/ https://www.ncbi.nlm.nih.gov/pubmed/34503244 http://dx.doi.org/10.3390/cancers13174434 |
Ejemplares similares
-
Emerging Role of CREB in Epithelial to Mesenchymal Plasticity of Pancreatic Cancer
por: Mehra, Siddharth, et al.
Publicado: (2022) -
Four potential microRNAs affect the progression of pancreatic ductal adenocarcinoma by targeting MET via the PI3K/AKT signaling pathway
por: Yao, Li-Chao, et al.
Publicado: (2021) -
KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas
por: Diehl, Adam C, et al.
Publicado: (2022) -
Apoptotic pathways in pancreatic ductal adenocarcinoma
por: Hamacher, Rainer, et al.
Publicado: (2008) -
Emerging targets in pancreatic cancer: epithelial–mesenchymal transition and cancer stem cells
por: Castellanos, Jason A, et al.
Publicado: (2013)